Supernus Pharmaceuticals Inc (fra:S49) Share Price

Company Profile

Business description
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
Contact
9715 Key West Avenue
RockvilleMD20850
USA
T: +1 301 838-2500
E: [email protected]
https://www.supernus.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
778

Recommended

Near-term pain, long-term potential.

Dan Baker | 22 October 2026

We see the company’s momentum in its core advertising business, as well as adoption of Muse, as early signals that the firm’s AI playbook is working.

Malik Ahmed Khan, CFA | 22 October 2026

Our increased valuation comes from higher full self-driving adoption assumptions and a lower near- and medium-term capital expenditures forecast.

Seth Goldstein, CFA | 22 October 2026

Index	Last price	Change	% Change
All Ordinaries	8,917.10	39.50	-0.44%
CAC 40	7,811.26	110.42	-1.39%
DAX 40	25,371.75	273.29	-1.07%
Dow JONES (US)	52,773.39	82.70	-0.16%
FTSE 100	10,725.03	27.85	-0.26%
HKSE	22,934.68	717.19	-3.03%
NASDAQ	25,938.03	764.82	-2.86%
Nikkei 225	62,907.84	1,713.40	-2.65%
NZX 50 Index	13,746.84	14.45	-0.11%
S&P 500	7,644.87	112.30	-1.45%
S&P/ASX 200	8,793.20	38.10	-0.43%
SSE Composite Index	3,658.03	55.00	-1.48%